Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Vitamin D may help to alleviate asthma exacerbation because of its anti-inflammation effect, but the evidence is inconsistent in childhood asthma. MiRNAs are important mediators in asthma pathogenesis and also excellent non-invasive biomarkers. We hypothesized that circulating miRNAs are associated with asthma exacerbation and modified by vitamin D levels.

Methods: We sequenced baseline serum miRNAs from 461 participants in the Childhood Asthma Management Program (CAMP). Logistic regression was used to associate miRNA expression with asthma exacerbation through interaction analysis first and then stratified by vitamin D insufficient and sufficient groups. Microarray from lymphoblastoid B-cells (LCLs) treated by vitamin D or sham of 43 subjects in CAMP were used for validation in vitro. The function of miRNAs was associated with gene modules by weighted gene co-expression network analysis (WGCNA).

Results: We identified eleven miRNAs associated with asthma exacerbation with vitamin D effect modification. Of which, five were significant in vitamin D insufficient group and nine were significant in vitamin D sufficient group. Six miRNAs, including hsa-miR-143-3p, hsa-miR-192-5p, hsa-miR-151a-5p, hsa-miR-24-3p, hsa-miR-22-3p and hsa-miR-451a were significantly associated with gene modules of immune-related functions, implying miRNAs may mediate vitamin D effect on asthma exacerbation through immune pathways. In addition, hsa-miR-143-3p and hsa-miR-451a are potential predictors of childhood asthma exacerbation at different vitamin D levels.

Conclusions: miRNAs are potential mediators of asthma exacerbation and their effects are directly impacted by vitamin D levels.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921757PMC
http://dx.doi.org/10.1186/s12931-024-02737-xDOI Listing

Publication Analysis

Top Keywords

asthma exacerbation
28
childhood asthma
16
mirnas associated
12
asthma
11
vitamin
11
circulating mirnas
8
mirnas
8
mediators asthma
8
associated asthma
8
vitamin insufficient
8

Similar Publications

Asthma is a chronic inflammatory respiratory disease influenced by genetic and environmental factors. Emerging evidence suggests that microplastics and nanoplastics (NPs) pose significant health risks. When inhaled, these tiny particles can accumulate in the lungs, triggering inflammation, oxidative stress, and other disruptions in pulmonary function.

View Article and Find Full Text PDF

Background: Although the benefits of biologics in severe asthma are well established, the optimal strategy to discontinue therapy remains controversial.

Aim: to evaluate clinical, functional, and laboratory course of children and adolescents with severe asthma after biological therapy withdrawal due to sustained good control. Secondary aim was to identify clinical or inflammatory markers predictive of asthma control after discontinuation.

View Article and Find Full Text PDF

Background: Asthma is the most common chronic paediatric condition and a frequent cause of emergency department visits and hospitalizations.

Objectives: The project objective was to decrease inpatient length of stay (LOS) for asthma exacerbations between May 2021 and 2022.

Methods: The Institute for Healthcare Improvement Model for improvement was employed to study if systemic changes to asthma management could reduce hospital LOS.

View Article and Find Full Text PDF

Introduction: Chronic rhinosinusitis with nasal polyp (CRSwNP) is a predominant type 2 inflammatory disease, affecting the sense of smell and quality of life. Loss of smell compromises physical and emotional health, creating negative impacts and its treatment in CRSwNP is challenging.

Aim: To present the outcomes of dupilumab in olfactory function, Nasal Polyp Score (NPS) and quality of life in Brazilian patients with severe CRSwNP.

View Article and Find Full Text PDF

Observational analysis of biological remission as a treatment target for severe asthma: UK severe asthma registry.

J Allergy Clin Immunol Pract

September 2025

Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK; Belfast Health and Social Care Trust, Belfast, UK.

Background: The aim of biologic therapies in severe asthma is inhibition of T2 inflammatory pathways.

Objective: We hypothesized that patients who achieve complete suppression of IL-5 & IL4/IL13 pathways with biologic therapy (FeNO <20ppb & blood eosinophil count (BEC) <0.15x10ˆ9, 'biological remission') would have better outcomes than patients with incomplete suppression of T2 biology.

View Article and Find Full Text PDF